Who Paid My Doc
Sarah Conlon
Medical Oncology Flagstaff, AZ Medical Doctor
NPI 1861425829 CMS profile 1042564
77 W Forest Ave Ste 301, Flagstaff, AZ 86001
General payments
$6,283
Research payments
$0
Ownership & investment interest
$653,809
Research they led as principal investigator
$51,563
Through program year 2025, Sarah Conlon of Flagstaff, AZ is reported in the CMS Open Payments database as having received $6,283 across 272 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $51,563 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $653,809 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 55th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,526 | 62 | |
| 2024 | General | $1,572 | 66 | |
| 2023 | General | $1,745 | 72 | |
| 2022 | General | $667 | 29 | |
| 2021 | General | $69 | 4 | |
| 2020 | General | $29 | 2 | |
| 2019 | General | $675 | 37 | |
| 2025 | Ownership | $349,997 | 1 | |
| 2024 | Ownership | $303,812 | 1 |
Beside peers
- Sarah Conlon
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Sarah Conlon were reported at $1,526. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Sarah Conlon | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $675 | $968 | $140–$6,658 | $163 |
| 2020 | $29 | $747 | $102–$5,891 | $114 |
| 2021 | $69 | $430 | $50–$4,098 | $132 |
| 2022 | $667 | $812 | $127–$4,907 | $149 |
| 2023 | $1,745 | $957 | $144–$5,248 | $160 |
| 2024 | $1,572 | $1,042 | $149–$5,650 | $164 |
| 2025 | $1,526 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 40 drugsPart D claims
1,127
Drug cost
$2,333,067
Branded share of claims
22.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pomalyst Pomalidomide | Brand | 16 | $369,680 | |
| Ibrance Palbociclib | Brand | 23 | $357,077 | |
| Xtandi Enzalutamide | Brand | 29 | $333,869 | |
| Jakafi Ruxolitinib Phosphate | Brand | 21 | $330,521 | |
| Venclexta Venetoclax | Brand | 21 | $299,511 | |
| Nubeqa Darolutamide | Brand | 23 | $273,562 | |
| Verzenio Abemaciclib | Brand | 17 | $196,621 | |
| Abiraterone Acetate | Generic | 35 | $94,651 | |
| Orgovyx Relugolix | Brand | 12 | $31,539 | |
| Eliquis Apixaban | Brand | 15 | $12,335 |
The 10 drugs with the highest cost, of 40 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 148 billing codesPaid by Medicare
$3,216,533
Medicare patients
470
Services billed
146,847
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 65% | |
| Cancer | 49% | |
| Arthritis | 36% | |
| Diabetes | 30% | |
| Ischemic heart disease | 26% | |
| Chronic kidney disease | 22% | |
| Depression | 16% | |
| COPD | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 19 | 25,200 | $1,125,858 |
| Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130 | Office | 11 | 432 | $65,806 |
| Injection, denosumab, 1 mg J0897 | Office | 19 | 2,760 | $56,446 |
| Injection, aprepitant, 1 mg J0185 | Office | 26 | 12,350 | $16,572 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 18 | 97 | $13,691 |
| Injection, docetaxel, 1 mg J9171 | Office | 14 | 4,466 | $2,989 |
| Injection, carboplatin, 50 mg J9045 | Office | 16 | 470 | $1,332 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 39 | 1,505 | $1,089 |
| Injection, paclitaxel, 1 mg J9267 | Office | 12 | 9,337 | $766 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 59 | 2,742 | $248 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 51 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| TIVDAK |
|
$112 | — | — |
| OPDIVO |
|
$102 | — | — |
| EPKINLY |
|
$73 | — | — |
| AYVAKIT |
|
$62 | — | — |
| Padcev |
|
$50 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 51 with PatronRecords
272 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Medical Oncology in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.